Moderna Cuts Borrowing Margins On $1.5 Billion Credit Deal And Pushes Repayment To 2031
The revised agreement extends borrowing windows, but access to $500 million still hinges on an eligible product winning FDA approval.
Moderna, which develops mRNA medicines and vaccines, secured lower borrowing margins and a later repayment deadline under its $1.5 billion agreement. The changes took effect Monday, November 9, according to an 8-K filed Monday, and move scheduled loan repayment to November 24, 2031, from November 24, 2030.
Lower Surcharges, Later Repayment
Moderna and its lenders, with Ares Capital acting as their agent, cut the interest margins on initial and delayed-draw loans by 0.75 percentage points.
Loans linked to the Secured Overnight Funding Rate, or SOFR, now carry a 4.75% surcharge, down from 5.50%. The margin on base-rate loans fell to 3.75% from 4.50%; those margins are added to the underlying benchmark rates.
The later maturity remains subject to provisions allowing earlier repayment. Moderna established the financing on November 19, 2025, allocating $600 million to initial term loans for working capital and general corporate purposes. Collateral, with exclusions, and guarantees from participating subsidiaries continue to back the obligations.
FDA Approval Still Gates $500 Million
Moderna has until November 24, 2029, to borrow against both delayed-draw commitments, subject to earlier termination. The $400 million commitment previously expired on November 24, 2027; the $500 million portion previously expired on November 24, 2028.
Access to that $500 million still requires FDA approval of an eligible product. Qualifying candidates include Moderna's combined COVID-flu vaccine, its flu vaccine and its norovirus vaccines.
The revised agreement also allows unsecured borrowing convertible into shares or cash. That debt is capped at 10% of Moderna's market capitalization when issued, with restrictions on maturity, covenants and other terms.
COVID Sales Support A Wider Pipeline
Moderna reported $1.9 billion in revenue for 2025, largely from COVID vaccines. Its commercial products are Spikevax and mNEXSPIKE for COVID, plus mRESVIA against respiratory syncytial virus, or RSV.
Its development pipeline includes 35 vaccine and therapeutic programs, six in late-stage development, covering infectious diseases, cancer and rare diseases. Moderna works with Merck on an individualized cancer therapy and with Recordati on a rare disease treatment.
The company operates a global manufacturing network, including facilities it built and manages in the UK, Canada and Australia.
The longer borrowing window preserves time to meet the product-approval condition; FDA clearance remains the gate to the $500 million portion.
Sources
- 8-K Filing — Moderna, Inc. (MRNA) — SEC EDGAR
- Exhibit moderna-firstamendmentexec.htm — Moderna, Inc. 8-K exhibit — SEC EDGAR